Scinai Immunotherapeutics Updates Corporate Presentation for January 2024

TL;DR

**Scinai just dropped its updated January 2024 corporate presentation, giving investors the latest business overview.**

AI Summary

Scinai Immunotherapeutics Ltd. filed a 6-K on January 18, 2024, to provide an updated corporate presentation for January 2024. This presentation, furnished as Exhibit 99.1, offers new information about the company's business, though Scinai notes these updates are not an admission of materiality. For investors, this matters because it provides the latest official overview of Scinai's strategic direction and pipeline, which could influence their perception of the company's future prospects and stock value.

Why It Matters

This filing gives investors the most current official information on Scinai's business strategy and developments, which can help them make informed decisions about holding or buying the stock.

Risk Assessment

Risk Level: low — This filing is purely informational, providing an updated business presentation without disclosing any immediate financial or operational risks.

Analyst Insight

An investor should review the updated January 2024 corporate presentation (Exhibit 99.1) to understand Scinai's current business strategy and pipeline, cross-referencing it with previous filings for any significant changes or new disclosures.

Key Players & Entities

• Scinai Immunotherapeutics Ltd. (company) — the registrant filing the 6-K
• Amir Reichman (person) — Chief Executive Officer who signed the filing
• January 18, 2024 (date) — date of the 6-K filing

FAQ

From the Filing

0001213900-24-004354.txt : 20240118 0001213900-24-004354.hdr.sgml : 20240118 20240118115050 ACCESSION NUMBER: 0001213900-24-004354 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 35 CONFORMED PERIOD OF REPORT: 20240118 FILED AS OF DATE: 20240118 DATE AS OF CHANGE: 20240118 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37353 FILM NUMBER: 24540760 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 6-K 1 ea191801-6k_scinaiimmun.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Explanatory Note Scinai Immunotherapeutics Ltd. (the “Company”) has made available an updated presentation about its business, a copy of which is furnished herewith as Exhibit 99.1 and incorporated by reference. The new updates in the presentation are not an admission as to the materiality of any information therein. The information contained in the presentation is summary information that should be considered in the context of the Company’s filings with the Securities and Exchange Commission and other public announcements the Company may make by press release or otherwise from time to time. 1 Exhibit Index Exhibit No. Description 99.1 Scinai Immunotherapeutics Presentation dated January 2024. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: January 18, 2024 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 3 EX-99.1 2 ea191801ex99-1_scinaiimmun.htm SCINAI IMMUNOTHERAPEUTICS PRESENTATION DATED JANUARY 2024 Exhibit 99.1 CLICK TO EDIT MASTER TITLE STYLE CORPORATE PRESENTATION | JANUARY 2024 | NASDAQ: SCNI CLICK TO EDIT MASTER TITLE STYLE 2 SAFE HARBOR STATEMENT This communication contains forward - looking statements within the meaning of the Private Litigation Reform Act of 1995 . Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify such forward - looking statements . All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of the management of Scinai Immunotherapeutics Ltd . ("Scinai") are forward - looking statements . Examples of such statements include, but are not limited to, statements regarding the therapeutic and commercial potential of nanosized antibodies (NanoAbs) ; the pipeline market potential ; and the timing of NanoAb proof - of - concept studies and cli